Top 10 Medical AI Companies to Buy According to Analysts

5. Novo Nordisk A/S (NYSE:NVO)

Stock Upside Potential: 51.48%

Number of Hedge Fund Holders: 60

Novo Nordisk A/S (NYSE:NVO) is one of the top 10 medical AI companies to buy according to analysts. On July 29, Novo Nordisk announced that Maziar Mike Doustdar will become its new president and CEO, effective August 7, succeeding Lars Fruergaard Jørgensen. Doustdar, currently EVP of International Operations, has driven significant growth—doubling non-U.S. sales to DKK 112 billion by 2024, and leads a global workforce of 20,000. His appointment followed a rigorous internal and external selection process and received full backing from both the Board and the Novo Nordisk Foundation.

Chair Helge Lund praised Doustdar’s leadership, noting his talent for delivering results and building strong teams. Doustdar expressed deep commitment to pushing the company further in diabetes and obesity innovation, aiming to reach more patients globally. Lund also thanked outgoing CEO Jørgensen for his 34 years of service, highlighting the transformation and impact he had on millions of lives through Novo Nordisk’s medical breakthroughs.

Novo Nordisk A/S (NYSE:NVO) is a global healthcare company that focuses on developing and delivering innovative medicines and delivery systems for serious chronic diseases, particularly diabetes and obesity. It’s also investing in and utilizing Artificial Intelligence (AI) across various aspects of its operations, including drug discovery, development, and commercial activities, with a focus on accelerating innovation and improving patient outcomes.